Adjunctive therapies in the treatment of acute coronary syndromes

Mayo Clinic Proceedings

Volumn 76, Issue 4, 2001, Pages 391-405

  Miller, Wayne L ^a   Reeder, Guy S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLOPIDOGREL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; HIRUDIN; HIRULOG; ISOSORBIDE MONONITRATE; LIDOCAINE; LISINOPRIL; LOW MOLECULAR WEIGHT HEPARIN; NIFEDIPINE; STREPTOKINASE; THROMBIN INHIBITOR; TIROFIBAN; UNINDEXED DRUG; VERAPAMIL;

DRUG EFFICACY; DRUG MECHANISM; HEART INFARCTION; HUMAN; REPERFUSION; REVIEW; SECONDARY PREVENTION; ST SEGMENT ELEVATION; SURVIVAL; SYNDROME; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

EID: 0035082271     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)62387-2     Document Type: Review

References (103)

1. Dakik HA, Kleiman NS, Farmer JA, et al, Intensive médical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. Circulation. 1998;98:20172023.
2. Anderson HV, Cannon CP, Stone PH, et al, One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial: a randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction [published correction appears in J Am Coll Cardiol. 2000;35:263]. JAm Coll Cardiol. 1995;26:1643-1650.
3. Boden WE, O'Rourke RA, Crawford MH, et al, Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators, Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med. 1998;338:1785-1792.
4. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE, Adjunctive drug therapy of acute myocardial infarction-evidence from clinical trials. W Engl J Med. 1996:335:1660-1667.
5. Ryan TJ, Antman EM, Brooks NH, et al, 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 1999; 100:1016-1030.
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group, Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
7. Sharis PJ, Cannon CP, Loscalzo J, The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998;129:394-405.
8. CAPRIE Steering Committee, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
9. Bennett CL, Connors JM, Carwile JM, et al, Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773-1777.
10. Oosterga M, Anthonio RL, de Kam PJ, Kingma JH, Crijns HJ, van Gilst WH, Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol. 1998 ;81:1178-1181.
11. Kong DE, Califf RM, Miller DP, et al, Clinical outcomes of therapeutic agents that block the platelet glycoprotein Ilb/IIIa integrin in ischémie heart disease. Circulation. 1998;98:2829-2835.
12. Ryan TJ, Anderson JL, Antman EM, et al, ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328-1428.
13. Antman EM, Giugliano RP, McCabe CH, et al, TIMI 14 Investigators, Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: results of TIMI 14 trial [abstract]. J Am Coll Cardiol. 1998;31(suppl A):191A. Abstract 842-1.
14. Vorchheimer DA, Badimon JJ, Fuster V, Platelet glycoprotein Ilb/IIIa receptor antagonists in cardiovascular disease. JAMA. 1999:281:1407-1414.
15. Cannon C, Preliminary results of the OPUS-TIMI 16 trial. In: Program and abstracts of the 48th Annual Scientific Session of the American College of Cardiology; March 10, 1999; New Orleans, La.
16. Gruppo Italiano per lo Studio della Supravvivenza nellTnfarto Miocardico, GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336:65-71.
17. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group, ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,229 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
18. GUSTO Investigators, An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. ,/V Engl J Med. 1993;329:673-682.
19. Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ, Heparininduced thrombocytopenia. J Am Coll Cardiol. 1998;31:14491459.
20. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group, Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996;347:561-568.
21. Swahn E, Wallentin L, FRISC Investigators, Low-MolecularWeight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC). Am J Cardiol. 1997;80(5A):25E-29E.
22. Klein W, Buchwald A, Hillis WS, et al, FRIC Investigators, Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Am J Cardiol. 1997; 80(5A):30E-34E.
23. Cohen M, Demers C, Gurfmkel EP, et al, Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group, A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. NEnglJMed. 1997;337:447-452.
24. FRagmin and Fast Revascularisation During Instability in Coronary Artery Disease (FRISC II) Investigators, Long-term lowmolecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:701-707.
25. Amman EM, McCabe CH, Gurfmkel EP, et al, TIMI 1 IB Investigators, Enoxaparin prevents death and cardiac ischémie events in unstable angina/non-Q-wave myocardial infarction: results of Thrombolysis In Myocardial Infarction (TIMI) 1 IB trial. Circulation. 1999;100:1593-1601.
26. Antman EM, Cohen M, Radley D, et al, TIMI 1 IB (Thrombolysis In Myocardial Infarction) and ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events) Investigators, Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 1 IBESSENCE meta-analysis. Circulation. 1999; 100:1602-1608.
27. Cannon CP, McCabe CH, Henry TD, et al, A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol. 1994;23:993-1003.
28. Lee LV, McCabe CH, Antman EM, et al, TIMI 6 Investigators, Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the TIMI 6 trial [abstract]. J Am Coll Cardiol. 1994;23(special issue):344A. Abstract 788-2.
29. Ferguson JJ, Meeting highlights: American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 24 to 27, 1996. Circulation. 1996;94:l-5.
30. Ferguson JJ, Meeting highlights: 46th Annual Scientific Sessions of the American College of Cardiology [published correction appears in Circulation. 1997;96:4118]. Circulation. 1997;96:367371.
31. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Ha Investigators, Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631 -1637.
32. Antman EM, TIMI 9A Investigators, Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation. 1994;90:1624-1630.
33. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) lib Investigators, A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N EnglJMed. 1996;335:775-782.
34. Antman EM, TIMI 9B Investigators, Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
35. Yusuf S, Anand S, Avezum A Jr, Flather M, Coutinho M, Treatment for acute myocardial infarction: overview of randomized clinical trials. Eur Heart J. 1996;17(suppl F): 16-29.
36. Hjalmarson A, Elmfeldt D, Herlitz J, et al, Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet. 1981;2:823-827.
37. MIAMI Trial Research Group, Metoprolol in acute myocardial infarction (MIAMI): a randomised placebo-controlled international trial. Eur Heart J. 1985;6:199-226.
38. First International Study of Infarct Survival Collaborative Group, Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;2:5766.
39. Norwegian Multicenter Study Group, Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
40. ß-Blocker Heart Attack Trial Research Group, A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA. 1982;247:1707-1714.
41. Roberts R, Rogers WJ, Mueller HS, et al, TIMI Investigators, Immediate versus deferred ß-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study. Circulation. 1991;83:422-437.
42. McCormick D, Gurwitz JH, Lessard D, Yarzebski J, Gore JM, Goldberg RJ, Use of aspirin, ß-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? Arch Intern Med. 1999;159:561567.
43. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L, Adverse outcomes of underuse of ßblockers in elderly survivors of acute myocardial infarction. JAMA. 1997;277:115-121.
44. Jugdutt BI, Warnica JW, Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage, and infarct location [published correction appears in Circulation. 1989;79:1151]. Circulation. 1988;78:906919.
45. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group, ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-685.
46. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico, GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994; 343:1115-1122.
47. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H, CONSENSUS II Study Group, Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327: 678-684.
48. Chinese Cardiac Study Collaborative Group, Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS1). Lancet. 1995;345:686-687.
49. Pfeffer MA, Braunwald E, Moyé LA, et al, SAVE Investigators, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med. 1992; 327:669-677.
50. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators, Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
51. K0ber L, Torp-Pedersen C, Carlsen JE, et al, Trandolapril Cardiac Evaluation (TRACE) Study Group, A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
52. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA, Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1999;33:598-604.
53. Heart Outcomes Prevention Evaluation Study Investigators, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342:145-153.
54. Wilcox RG, Hampton JR, Banks DC, et al, Trial of early nifedipine in acute myocardial infarction: the Trent study. BMJ. 1986;293:1204-1208.
55. Israeli SPRINT Study Group, Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 1988;9:354-364.
56. SPRINT Study Group, The Secondary Prevention Re-infarction Israeli Nifedipine Trial (SPRINT) II: design and methods [abstract]. Eur Heart J. 1988;9(suppl 1):350. Abstract 1914.
57. Multicenter Diltiazem Postinfarction Trial Research Group, The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385-392.
58. Danish Study Group on Verapamil in Myocardial Infarction, Verapamil in acute myocardial infarction. Eur Heart J. 1984;5: 516-528.
59. Danish Study Group on Verapamil in Myocardial Infarction, Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial IIDAVITII). Am J Cardiol. 1990;66:779-785.
60. MacMahon S, Collins R, Peto R, Koster RW, Yusuf S, Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. JAMA. 1988;260:1910-1916.
61. Alexander JH, Granger CB, Sadowski Z, et al, GUSTO-I and GUSTO-IIb Investigators, Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. Am Heart J. 1999;137:799-805.
62. Teo KK, Yusuf S, Furberg CD, Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA. 1993; 270:1589-1595.
63. Cairns JA, Connolly SJ, Roberts R, Gent M, Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators, Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet. 1997;349:675-682.
64. Julian DG, Camm AJ, Frangin G, et al, European Myocardial Infarct Amiodarone Trial Investigators, Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349:667-674.
65. Amiodarone Trials Meta-Analysis Investigators, Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 1997;350:14171424.
66. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D, Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basal Antiarrhythmic Study of Infarct Survival (BASIS). JAm Coll Cardiol. 1990;16:1711-1718.
67. Blankenhorn DH, Azen SP, Kramsch DM, et al, MARS Research Group, Coronary angiographie changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;! 19:969-976.
68. Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
69. Sacks FM, Pfeffer MA, Moye LA, et al, Cholesterol and Recurrent Events Trial Investigators, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
70. Pitt B, Waters D, Brown WV, et al, Atorvastatin versus Revascularization Treatment Investigators, Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999;341:70-76.
71. LaRosa JC, He J, Vupputuri S, Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
72. Teo KK, Yusuf S, Collins R, Held PH, Peto R, Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ. 1991;303:1499-1503.
73. Woods KL, Fletcher S, Roffe C, Haider Y, Intravenous magnesium sulphate in suspected acute myocardial infarction: results of
74. the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2), Lancet. 1992;339:1553-1558.
75. Magnesium in Coronaries (MAGIC), Available at: www.nhlbi .nih.gov/studies/magicweb.htm. Accessibility verified March 9, 2001.
76. Moss AJ, Davis HT, Conard DL, DeCamilla JJ, Odoroff CL, Digitalis-associated cardiac mortality after myocardial infarction. Circulation. 1981;64:1150-1156.
77. Bigger JT Jr, Fleiss JL, Rolnitzky LM, Merab JP, Ferrick KJ, Effect of digitalis treatment on survival after acute myocardial infarction. Am J Cardiol. 1985;55:623-630.
78. Digitalis Subcommittee of the Multicenter Post-Infarction Research Group, The mortality risk associated with digitalis treatment after myocardial infarction. Cardiovasc Drugs Ther. 1987; 1 : 125-132.
79. Digitalis Investigation Group, The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336:525-533.
80. Stampfer MJ, Colditz GA, Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991 ;20:47-63.
81. Sidney S, Petitti DB, Quesenberry CP Jr, Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med. 1997;127:501-508.
82. Hulley S, Grady D, Bush T, et al, Heart and Estrogen/progestin Replacement Study (HERS) Research Group, Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605613.
83. Herrington DM, Reboussin DM, Brosnihan KB, et al, Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-529.
84. Abrams J, Late-breaking clinical trials: American College of Cardiology: American College of Cardiology Scientific Sessions, March 12-15, 2000, Anaheim, ÇA. Clin Cardiol Alert. 2000; 19(No. 5):33-40.
85. Fath-Ordoubadi F, Beatt KJ, Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 1997;96:11521156.
86. Dfaz R, Paolasso EA, Piegas LS, et al, ECLA (Estudios Cardiolögicos Latinoamérica) Collaborative Group, Metabolic modulation of acute myocardial infarction: the ECLA glucose-insulinpotassium pilot trial. Circulation. 1998;98:2227-2234.
87. Malmberg K, DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infaction) Study Group, Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 1997:314:1512-1515.
88. Malmberg K, Norhammar A, Wedel H, Rydén L, Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and InsulinGlucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999;99:2626-2632.
89. Herbaczynska-Cedro K, Klosiewicz-Wasek B, Cedro K, Wasek W, Panczenko-Kresowska B, Wartanowicz M, Supplementation
90. with vitamins C and E suppresses leukocyte oxygen free radical production in patients with myocardial infarction, Eur Heart J. 1995; 16:1044-1049.
91. Virtamo J, Rapola JM, Ripatti S, et al, Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med. 1998; 158: 668-675.
92. Singh RB, Niaz MA, Rastogi SS, Rastogi S, Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian Experiment of Infarct Survival-3). Am J Cardiol. 1996;77: 232-236.
93. Muhlestein JB, Hammond EH, Carlquist JF, et al, Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 1996;27:1555-1561.
94. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT, Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:841-849.
95. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ, Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
96. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH, Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation. 1999;99: 1161-1164.
97. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, ROXIS Study Group, Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet. 1997;350:404407.
98. Anderson JL, Muhlestein JB, Carlquist J, et al, Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation. 1999;99:1540-1547.
99. Becker RC, Burns M, Gore JM, et al, National Registry of Myocardial Infarction (NRMI-2) Participants, Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. Am Heart J. 1998; 135:786796.
100. Rogers WJ, Bowlby LJ, Chandra NC, et al, Participants in the National Registry of Myocardial Infarction, Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation. 1994;90:2103-2114.
101. SOLVD Investigators, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions [published correction appears in N Engl J Med. 1992;327:1768]. NEnglJMed. 1992;327: 685-691.
102. Forman R, Aronow WS, Management of postmyocardial infarction in the elderly patient. Clin Geriatr Med. 1996; 12:169-180.
103. Phibbs B, Marcus F, Marriott HJ, Moss A, Spodick DH, Q-wave versus non-Q wave myocardial infarction: a meaningless distinction. JAm Coll Cardiol. 1999;33:576-582.